Thera-SAbDab

ZUBERITAMAB

>   Structural Summary
TherapeuticZuberitamab
TargetMS4A1/CD20
Heavy ChainEVQLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSS
Light ChainDIELSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv Structure3bky [Fvs: HL]
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Zuberitamab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 96.03%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 100E 101 102 103 104 105 106 107 108 109 110 111 112 113
zuberitamab E V Q L Q Q S G A E L V R P G A S V K M S C K A S G Y T F T S Y N M H W V K Q T P R Q G L E W I G A I Y P G N G D T S Y N Q K F K G K A T L T V D K S S S T A Y M Q L S S L T S E D S A V Y F C A R V V Y Y S N S Y W Y F D V W G T G T T V T V S S
3bky - A Y L Q Q S G A E L V R P G A S V K M S C K A S G Y T F T S Y N M H W V K Q T P R Q G L E W I G A I Y P G N G D T S Y N Q K F K G K A T L T V D K S S S T A Y M Q L S S L T S E D S A V Y F C A R V V Y Y S N S Y W Y F D V W G T G T T V T V S A

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
zuberitamab D I E L S Q S P A I L S A S P G E K V T M T C R A S S S V S - Y M H W Y Q Q K P G S S P K P W I Y A P S N L A S G V P A R F S G S G S G T S Y S L T I S R V E A E D A A T Y Y C Q Q W S F N P P T F G A G T K L E I K
3bky Q I V L S Q S P A I L S A S P G E K V T M T C R A S S S V - S Y M H W Y Q Q K P G S S P K P W I Y A P S N L A S G V P A R F S G S G S G T S Y S L T I S R V E A E D A A T Y Y C Q Q W S F N P P T F G A G T K L E L K
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (Aug '24)Phase-II
Estimated Status (Aug '24)Discontinued
Recorded Developmental Technology
INN Year Proposed2019
INN Year Recommended2020
Companies InvolvedZhejiang Hisun Pharmaceutical
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedDiffuse large B-cell lymphoma
NotesRituximab biosimilar

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy